Filing Details

Accession Number:
0001209191-14-056122
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-05 16:05:14
Reporting Period:
2014-09-03
Filing Date:
2014-09-05
Accepted Time:
2014-09-05 16:05:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1113148 Infinity Pharmaceuticals Inc. INFI Pharmaceutical Preparations (2834) 330655706
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1492805 J. Vito Palombella C/O Infinity Pharmaceuticals, Inc.
780 Memorial Drive
Cambridge MA 02139
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-03 7,105 $2.04 7,105 No 4 M Direct
Common Stock Acquisiton 2014-09-03 2,367 $2.04 9,472 No 4 M Direct
Common Stock Disposition 2014-09-03 9,472 $15.39 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-09-03 7,105 $0.00 7,105 $2.04
Common Stock Stock Option (right to buy) Disposition 2014-09-03 2,367 $0.00 2,367 $2.04
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2005-05-10 2015-05-10 No 4 M Direct
0 2005-05-10 2015-05-10 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,388 Indirect By 401k
Footnotes
  1. The acquisition and disposition reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013.
  2. The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013.
  3. This stock option was granted under the issuer's Pre-Merger Stock Incentive Plan, which permits the early exercise of unvested stock options in exchange for shares of restricted stock that are subject to a right of repurchase by the issuer that lapses in accordance with the vesting schedule of the original option. This option is fully vested.